Tripos Names New VP of Business Development and Strategic Alliances, Discovery Research
News Dec 16, 2005
Tripos, Inc. has announced that it has appointed Dr. Tom Mander as vice president of business development and strategic alliances, Discovery Research.
In his new role, Mander will be responsible for identifying new business development opportunities, establishing strategic alliances, developing intellectual property, and driving marketing initiatives for Tripos Discovery Research, Ltd. (TDR), which is located in Bude, England.
"Tom possesses an ideal blend of scientific expertise, leadership skills and international business development experience that will contribute to TDR’s continued evolution," said Dr. Mark Allen, senior vice president and managing director of TDR.
Mander brings 13 years of experience in small molecule drug discovery to Tripos. For the past six and a half years, Mander has held a variety of operational and commercial roles at Evotec, including department manager, product manager and vice president of business development.
He is credited with pioneering Evotec’s biological service offerings, launching several new products lines including Compound Management, establishing new strategic partnerships, and creating new business models.
Before joining Evotec, Mander was a group leader at Glaxo Wellcome, and held senior scientific roles at Xenova Ltd., the Centre for Natural Product Research (now MerLion) and Amersham International (now GE Healthcare).
"I am delighted to have joined Tripos Discovery Research," Mander said.
"It has established an unsurpassed level of expertise in high throughput parallel and analytical chemistry in a truly unique location conducive to innovation and creativity on behalf of its partners."
"I am looking forward to utilizing my experience to drive the company forward as we begin a new era at Tripos."
Mander holds a Doctor of Philosophy degree in a study of the physiological roles of microglia (brain macrophages) from the University of Oxford, a master of business administration degree from the Open University, and a bachelor’s degree in medical biochemistry from the School of Biological Sciences at the University of Surrey.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE